抑制癌症治疗多药耐药性的纳米药物递送体系

Nanoscale drug delivery systems for inhibiting multidrug resistance in cancer therapy

摘要:

多药耐药(Multi-drug resistance，MDR)是指肿瘤细胞对传统和新型化疗药物产生耐药性的现象，成为治疗恶性肿瘤的重要障碍。近年来，人们发现纳米药物递送体系(Nanoscale drug delivery systems ，NDDS)在抑制肿瘤多药耐药性方面表现出其独特优势，包括增加药物的溶解度和稳定性，避开药物外排泵、以更低的剂量和更少的副作用实现目标部位更高的药物浓度。因此，NDDS成为克服癌症MDR的有效策略。在这里，我们总结了近几年提高抗癌药物摄取和选择性细胞内蓄积的NDDS的种类及研究进展，包括靶向特异性配体功能化体系和刺激响应型药物的激活释放体系等。

Abstract:

Multi-drug resistance (MDR) refers to the phenomenon that tumor cells product resistant to traditional and new chemotherapeutic drugs, which has become an important obstacle in the treatment of malignant tumors. In recent years, it has been found that nanoscale drug delivery systems (NDDS) have unique advantages in inhibiting tumor multi-drug resistance, including increasing the solubility and stability of drugs, avoiding drug efflux pumps, achieving higher drug concentrations at the target site via using lower doses and negligible toxic side effects. Therefore, NDDS emerge as an effective strategy to overcome MDR in cancer. Here, we review the types and research progress of NDDS for enhancing the uptake of anticancer drugs and selective intracellular accumulation, including targeting specific ligand functionalization systems and stimulus-responsive drug activation and release systems.